Soligenix Faces Nasdaq Delisting Threat and Terminates Lead Drug Program
SNGX sits 54% above its 52-week low of $0.28 on light trading volume (0.1× avg).
Summary
Soligenix received a Nasdaq delisting notice and formally terminated its HyBryte™ drug development program, intensifying financial and operational challenges.
Key Events · Legal and Risk Events · SNGX
-
Nasdaq Delisting Notice Received
Soligenix received a notice from Nasdaq for non-compliance with the $1.00 minimum bid price rule, initiating a 180-day period to regain compliance by December 7, 2026.
-
HyBryte™ Development Program Terminated
Following the previously reported futility halt of its pivotal Phase 3 trial, the Board formally decided to terminate the HyBryte™ development program.
-
Strategic Options Under Review
With the termination of its lead program, the company will now evaluate strategic alternatives, including potential mergers, acquisitions, or advancing other pipeline assets.
-
Consulting CMO Role Ends
Dr. Richard Straube's role as Consulting Chief Medical Officer concluded, directly linked to the termination of the HyBryte™ program.
Analysis · SNGX · Life Sciences
Soligenix received a Nasdaq delisting notice for failing to meet the $1.00 minimum bid price, giving it until December 7, 2026, to regain compliance. This comes as the company formally terminates its HyBryte™ development program, a decision following the Phase 3 trial's futility halt in April. These events compound existing financial distress, including a going concern warning and ongoing dilutive ATM sales, forcing the company to explore strategic alternatives.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 41% of the 324 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNGX was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $0.28 to $6.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.